
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01974 | 38.4046692607 | 0.0514 | 0.0775 | 0.0514 | 6188 | 0.07135796 | CS |
4 | -0.01556 | -17.9469434833 | 0.0867 | 0.092 | 0.0514 | 9381 | 0.0742269 | CS |
12 | -0.001954 | -2.67327003584 | 0.073094 | 0.1269 | 0.0514 | 21503 | 0.08336124 | CS |
26 | -0.02386 | -25.1157894737 | 0.095 | 0.1269 | 0.0514 | 22213 | 0.08385596 | CS |
52 | -0.00386 | -5.14666666667 | 0.075 | 0.15 | 0.0514 | 23054 | 0.08881027 | CS |
156 | -0.05998 | -45.7443563148 | 0.13112 | 0.1942 | 0.0309 | 29477 | 0.08921523 | CS |
260 | -0.05516 | -43.6737925574 | 0.1263 | 2.21 | 0.0309 | 49869 | 0.36483258 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales